Evidence map›Paper›PMID 36852689›Full record

ArticleDrug delivery2023

Exploration of the inhibition action of TPGS on tumor cells and its combined use with chemotherapy drugs.

Lan Tang, Kaijuan Huang, Wenhui Jiang, Lulu Fu, Ran Zhang, Liting Shen, Zhimin Ou, Ye Huang, Zhenhai Zhang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug delivery, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Lan TangCollege of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China.
Kaijuan HuangCollege of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China.
Wenhui JiangCollege of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China.
Lulu FuCollege of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China.ORCID 0000-0002-8667-5126
Ran ZhangCollege of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China.
Liting ShenCollege of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China.
Zhimin OuCollege of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou, China.
Ye HuangZhejiang Institute of Dermatology Prevention and Treatment, Huzhou, China.
Zhenhai ZhangAffiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
Zhejiang University of Technology · CNNanjing University of Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS) is a commonly used nonionic surfactant used as a pharmaceutical carrier in different drug delivery systems. TPGS can reverse P-glycoprotein (P-gp)-mediated multidrug resistance (MDR) and also has anticancer activities. It suggests that when designing antitumor drug preparation, it's necessary to take into account the antitumor activity of TPGS. Our in vivo studies showed that TPGS exerted the strongest cytotoxicity in MCF-7-ADR cells when compared with seven other tumor cell lines. The further study revealed TPGS caused apoptosis and blocked MCF-7 cell growth in G2/M phase. Mechanistic insights suggested that TPGS increased intracellular calcium ion concentrations, leading to apoptosis via the mitochondrial pathway. Furthermore, two in vivo experiments were performed. One was TPGS, and DOX solution was administered by tail vein injection on MCF-7-ADR tumor bearing nude mice. The other was temperature sensitive TPGS gel (TPGS-TG) was administered by intratumoral injection on MCF-7-ADR tumor bearing nude mice combined with paclitaxel albumin nanoparticles (Abraxane

Indexed as

Albumin-Bound PaclitaxelATP Binding Cassette Transporter, Subfamily B, Member 1AnimalsATP Binding Cassette Transporter, Subfamily BMiceMice, NudeVitamin EAlbumin-Bound PaclitaxelATP Binding Cassette Transporter, Subfamily BATP Binding Cassette Transporter, Subfamily B, Member 1tocophersolanVitamin Eantitumorco-administrationD-α-Tocopheryl polyethylene glycol 1000 succinateintracellular calcium ion concentrationmarketed chemotherapeutic agents

Identifiers

PMID36852689
PMCPMC9980031
OpenAlexW4322616926

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.